CAS 151126-32-8: Pramlintide

Pramlintide is a synthetic, short-acting insulinotropic peptide that has been shown to reduce postprandial glucagon secretion and delay gastric emptying. It also has a number of physiological effects, including the activation of ATP-sensitive potassium channels, inhibition of oxidative phosphorylation, and induction of mitochondrial membrane potential. Pramlintide is approved for use in the treatment of type 1 and type 2 diabetes mellitus. The drug binds to the glucagon receptor on pancreatic alpha cells and stimulates insulin release from beta cells in a glucose-dependent manner. Pramlintide has been shown to have no significant effect on glycemic control when used as an adjunct to insulin therapy in patients with type 2 diabetes mellitus. This drug may also cause hypoglycemia when used alone or with other antihyperglycemic agents such as sulfonylureas or meglitinides.

Applications Pramlintide-d3 is labelled Pramlintide (P700800) which is an analogue of human amylin used in the treatment of insulin dependent diabetes. References Young, A.A. et al.: Drug Dev. Res., 37, 231 (1996); Colburn, W.A. et al.: J. Clin. Pharmacol., 36, 13 (1996); Kolterman, O.G. et al.: Diabetologia, 39, 492 (1996);

Pramlintide is a synthetic analog for amylin pancreatic peptide that has been used for the treatment of Type I and Type II Diabetes as a tool for glycemic control, stimulating glucose production and reducing appetite. This product has disulfide bonds between Cys2 and Cys7 and is available in the trifluoroacetate salt form.